This is Dr. Akana’s story.
How to sell an addiction treatment center at the right time, to the right buyer, for the right price was the question Dr. Kalena Akana had been turning over in her head for almost six months before she picked up the phone. When the right time came, Kalena called CGK Business Sales. Kalena, age 51, board-certified in addiction medicine and Native Hawaiian by birth, ran an $8.5M revenue, $2.1M EBITDA four-clinic outpatient substance use disorder treatment platform across the Houston metro, with the main clinic on Memorial Drive in West Houston, a Sugar Land satellite in Fort Bend County, a Pearland satellite in Brazoria County, and a Cypress satellite in northwest Harris County. Sixty-four W-2 employees ran the four sites: Kalena herself as Medical Director, four staff physicians (three MDs board-certified in addiction medicine plus one psychiatrist for dual-diagnosis cases), eighteen LCDC, LPC, and LMFT counselors, twelve RN and LVN clinical staff, eight case managers, fourteen administrative, billing, and intake personnel, and eight compliance and quality team members. The platform was clinically deep on purpose, because addiction treatment buyers underwrite clinical bench depth before they underwrite anything else. Kalena’s revenue mix was 50 percent medication-assisted treatment (Suboxone, Sublocade, Vivitrol, the regulated core of the practice with DEA X-waiver compliance documented across all four prescribing physicians), 30 percent intensive outpatient (nine-to-nineteen hours per week of structured therapy), 15 percent partial hospitalization (twenty-to-thirty hours per week, the most clinically intensive non-residential level), and 5 percent telehealth-delivered MAT for rural Texas patients via her Texas-licensed-physician network. The single most important operating fact about the practice (the fact that drove the eventual multiple) was the 90 percent in-network payor base Kalena had built deliberately over eleven years. Thirty-five percent of her revenue came from the major commercial carriers (Blue Cross Blue Shield Texas, Aetna, UnitedHealthcare, Cigna, Humana, all in-network). Thirty percent came from Texas Medicaid (Superior Health Plan, Molina, UnitedHealthcare Community Plan, all in-network). Fifteen percent came from Tricare West (in-network for SUD treatment serving Houston-area military families). Ten percent came from direct private-pay patients. Ten percent came from Medicare Part B, billed successfully via the bundled MAT and medical-management codes. Approximately 3,200 active patients sat on the active treatment cohort across the four sites at any given time, with the average length of stay in the MAT program at 14 months and the active cohort growing roughly 6 percent per quarter through hospital ER referrals from Memorial Hermann, Houston Methodist, and the HCA Houston Healthcare network, self-pay self-referrals driven by the in-network status, and the parole and probation referral pipeline through Harris County and Fort Bend County criminal justice diversion programs. The practice was CARF-accredited (only about 22 percent of US SUD outpatient providers carry CARF). She held a 4.8-star Google rating across more than 380 patient and family reviews and a measured 78 percent twelve-month MAT retention rate, against an industry average closer to 50 to 60 percent. Kalena’s mother in Honolulu was diagnosed with Parkinson’s late in 2025. She needed to spend more time in Hawaii. Her husband Daniel, a pediatric oncologist at Texas Children’s Hospital, supported the timing. Their son David was a Stanford-bound senior at Memorial High School. Kalena wanted to step into a part-time medical-director-emeritus role post-close, fly back to Houston quarterly, and spend the bulk of her time in Hawaii through the Parkinson’s progression. She came to us because she did not know who else to talk to about how to sell an addiction treatment center at this size, with four clinics covering the high-density Houston metro substance use disorder population, a 90 percent in-network payor base that buyers had been calling her about for eighteen months, a CARF accreditation, a 78 percent MAT retention rate, and the operational rhythm she had built across eleven years. This page is what happened next, and what could happen for you. Kalena is a composite, not a single real CGK seller, but the patterns and details are pulled from real addiction treatment engagements.
The night before Kalena decided to sell an addiction treatment center.
Most physicians who decide to sell an addiction treatment center have been sitting with the question quietly for months before they finally reach for the phone. Kalena was no different. She was 51. For eleven years she had been the founding Medical Director of a four-clinic outpatient substance use disorder platform across the Houston metro, the physician who had personally signed the original lease in 2015 on the Memorial Drive main clinic in West Houston after she left the Houston Methodist addiction medicine division, the prescribing lead on the first Suboxone induction protocols, and the relationship lead on every payor contract across the platform. The practice did $8.5 million in annual revenue, $2.1 million in EBITDA at the upper end of large-band addiction outpatient norms (driven by the 90 percent in-network payor mix, the four-clinic geographic moat across the high-density Houston metro substance use disorder population, the CARF accreditation, the 78 percent twelve-month MAT retention rate, and the hospital-ER referral pipeline), and a 64-person W-2 team across the four sites. Kalena led the platform clinically as Medical Director. Three additional MDs board-certified in addiction medicine held the staff physician roles across the four clinics, and a psychiatrist anchored the dual-diagnosis caseload. Eighteen LCDC, LPC, and LMFT counselors carried the IOP, PHP, and outpatient counseling load. Twelve RN and LVN clinical staff handled medication administration, vital signs, and triage. Eight case managers coordinated parole-and-probation, hospital-discharge, and community-resource workflows. Fourteen administrative, billing, and intake personnel ran the front office across the four clinics, and an eight-person compliance and quality team owned the CARF survey readiness, the DEA X-waiver documentation, the state SUD licensing, and the payor credentialing rhythm. Approximately 3,200 active patients sat on the active treatment cohort at any given time. The active cohort grew roughly 6 percent per quarter through hospital ER referrals (about 28 percent of new patient acquisition came through the Memorial Hermann, Houston Methodist, and HCA Houston Healthcare ER discharge planning teams), self-pay self-referrals driven by the in-network status (the in-network differentiator was the largest word-of-mouth driver across the Houston metro substance use disorder population), and the Harris County and Fort Bend County criminal justice diversion programs (about 12 percent of new patient flow). Twelve-month MAT retention ran at 78 percent, against an industry average closer to 50 to 60 percent, the operational story a sophisticated buyer would underwrite first.
Why physicians decide to sell an addiction treatment center
The Friday Kalena finally submitted the form, she had been at the Memorial Drive main clinic for the morning intake huddle when her mother called from Honolulu with the latest neurology appointment update. Her mother, age 79, had been diagnosed with Parkinson’s late in 2025 and had been declining slightly each month since. Kalena’s husband Daniel, a pediatric oncologist at Texas Children’s Hospital, had been gentle but consistent in the conversations at the kitchen table over the prior six months: she had built something, the addiction treatment M&A market in 2025 and 2026 was extraordinarily active for in-network operators, the Parkinson’s progression would not wait, their son David was a Stanford-bound senior at Memorial High School and would be gone in a year, and the next chapter (a part-time medical-director-emeritus role from Hawaii with quarterly Houston visits) was waiting if she wanted it. Her four staff physicians, the three MDs board-certified in addiction medicine and the psychiatrist who anchored the dual-diagnosis cases, were committed to staying on post-close if the buyer kept the clinical-leadership structure intact and ran the four sites under their existing CARF accreditation umbrella. Kalena had been approached fourteen times in the prior eighteen months: nine times by PE-backed addiction treatment consolidators headquartered out of Nashville, Atlanta, Pittsburgh, and a handful of national platforms, three times by regional Texas-based behavioral health operators that were expanding their Gulf Coast footprint, and twice by a single hospital health system trying to vertically integrate a SUD outpatient platform into its discharge-planning pipeline. Kalena did not know what her platform was actually worth at $8.5 million revenue and $2.1 million EBITDA, with four clinics covering Memorial Drive, Sugar Land, Pearland, and Cypress, 3,200 active patients, a 90 percent in-network payor base, a CARF accreditation, a 78 percent MAT retention rate, the hospital-ER referral pipeline, the criminal-justice-diversion referral flow, and the bilingual English-Spanish counseling team she had built specifically to serve Houston’s large Spanish-speaking population. She did not know whether the firms calling her were the right buyers for her four staff physicians, her counseling team, or the brand she had built across the Houston metro. She did not know whether the 90 percent in-network status was a value driver or a structural premium-multiple anchor for a sophisticated PE-backed addiction treatment consolidator. She did not have a single peer in her life who had ever sold an outpatient SUD treatment platform at this size, payor mix, and multi-site footprint.
That is the night she found CGK and submitted the form. We called her back at 7:42 the next morning, while Kalena was at the Memorial Drive main clinic finishing the morning controlled-substances reconciliation with her director of nursing before the 9:00 a.m. clinical case conference.
The first call about how to sell an addiction treatment center.
The first call was 52 minutes. We did most of the listening.
Physicians who think about how to sell an addiction treatment center in their early fifties, like Kalena, usually carry the same handful of pressures into the first call. Kalena talked about her four staff physicians (the three MDs board-certified in addiction medicine and the psychiatrist who carried the dual-diagnosis caseload), about the way each had become a clinical anchor at one of the four sites and a continuity figure for the long-tenure MAT patient cohort. She talked about the eighteen LCDC, LPC, and LMFT counselors who had built the IOP and PHP groups across the four clinics, three of whom had been with the practice for more than seven years. She talked about the twelve RN and LVN clinical staff who handled medication administration and triage, the eight case managers who coordinated the parole-and-probation, hospital-discharge, and community-resource workflows, the fourteen front-office administrative, billing, and intake personnel, and the eight-person compliance and quality team that owned the CARF survey, the DEA X-waiver documentation, the state SUD licensing, and the payor credentialing rhythm. She talked about the 3,200 active patients across the four sites, and the 14-month average length of stay in the MAT program. She talked about the 6 percent quarterly cohort growth, and the way the hospital-ER referral pipeline (Memorial Hermann, Houston Methodist, HCA Houston Healthcare) carried about 28 percent of new patient acquisition through ER discharge planning. She talked about the Harris County and Fort Bend County criminal justice diversion programs that delivered about 12 percent of new patient flow. She talked about the 90 percent in-network payor mix and the way she had deliberately negotiated each major commercial, Medicaid, and Tricare contract over eleven years rather than running an out-of-network billing model. She talked about the CARF accreditation and the way it placed her in the top 22 percent of US SUD outpatient providers. She talked about the 78 percent twelve-month MAT retention rate, against an industry average closer to 50 to 60 percent. She talked about the Methasoft electronic medical record and the Welkin scheduling platform she had standardized across the four clinics. She talked about the Hawaiian-American Houston community network that had driven her first 200 patients in 2015 to 2017. She talked about the bilingual English-Spanish counseling team she had built specifically to serve Houston’s large Spanish-speaking population. She talked about Daniel, her son David headed to Stanford, and her mother in Honolulu and the Parkinson’s progression. We asked about the platform the way you would ask if you were trying to understand it, not the way you would ask if you were trying to win the engagement. What we were listening for was not just the financials. We were listening for whether Kalena was actually ready to sell, what she was working toward, and whether her expectations on price were grounded in what the addiction treatment M&A market would actually support for an in-network, CARF-accredited, hospital-referred outpatient SUD platform of her size.
At the end of that call, we set up a working session: an in-person conversation where one of our Managing Directors would walk Kalena through our valuation model and tell her honestly what her platform was likely to command. We did not promise her a written report. Written valuations involve substantially more work, and we charge for those when a seller actually needs one for partnership buyout, estate planning, a divorce, or another documentary purpose. The walkthrough was free because Kalena was clearly thinking seriously about how to sell an addiction treatment center, the way someone thinks about it before they actually do it. Whether that ends up being in a year, five years, or longer, we make the same call.
The valuation session was the following Tuesday at 7:00 a.m. at the Memorial Drive main clinic, before the 8:30 a.m. clinical case conference and after Kalena had finished her controlled-substances reconciliation walk with the director of nursing.
Kalena was not ready to sell an addiction treatment center yet. She went home and waited four months.
The valuation session showed Kalena that her platform was worth meaningfully more than she had been hoping in some areas and meaningfully less in others, which is how these conversations usually go. The 90 percent in-network payor mix (the single most important value driver for an addiction treatment platform in 2026, because PE-backed consolidators structurally discount or refuse to acquire out-of-network operators), the four-clinic geographic moat across the high-density Houston metro substance use disorder population, the CARF accreditation that placed her in the top 22 percent of US SUD outpatient providers, the 78 percent twelve-month MAT retention rate against an industry average closer to 50 to 60 percent, the hospital-ER referral pipeline that delivered 28 percent of new patient acquisition through Memorial Hermann, Houston Methodist, and HCA Houston Healthcare ER discharge planning, the criminal-justice-diversion referral flow that delivered 12 percent of new patient flow through Harris County and Fort Bend County programs, the Methasoft and Welkin technology standardization across the four clinics, the DEA X-waiver compliance documented across all four prescribing physicians, the eleven-year operating history under a single physician founder, and the bilingual English-Spanish counseling capacity were all premium-multiple drivers a sophisticated PE-backed addiction treatment consolidator would pay up for. Three issues, though, were dragging the number down. The first was the per-clinic CARF survey-readiness binder variance. The Memorial Drive main clinic carried a tight, audit-ready binder owned by the eight-person compliance and quality team. The three satellites (Sugar Land, Pearland, Cypress) carried thinner binders that had not been refreshed in the prior twelve months. A buyer’s diligence team was going to pressure-test per-clinic CARF survey readiness as part of LOI formulation, because CARF survey continuity is a buyer-side regulatory-risk factor that translates directly into multiple. The second was the payor credentialing-and-renewal calendar documentation. Kalena knew her 90 percent in-network mix had been built deliberately over eleven years through individual contract negotiation, but she had not built a unified credentialing-and-renewal calendar that documented the next-renewal-date, the contract anniversary, the negotiated reimbursement rate, and the per-clinic credentialing status across each major commercial carrier (BCBS Texas, Aetna, UnitedHealthcare, Cigna, Humana), each Texas Medicaid managed care organization (Superior Health Plan, Molina, UnitedHealthcare Community Plan), Tricare West, and Medicare Part B. A sophisticated PE-backed consolidator’s underwriter was going to want a single-source credentialing calendar to confirm continuity of the in-network premium through the post-close integration window. The third was the patient-cohort retention curve documentation. Kalena knew her blended twelve-month MAT retention rate was 78 percent, but she had not built a documented cohort retention curve that broke retention out by program (MAT, IOP, PHP, telehealth MAT), by payor type (commercial, Medicaid, Tricare, private pay, Medicare), and by clinic location. A buyer’s investment committee was going to want the cohort curve to underwrite the recurring-revenue thesis on the practice.
We told Kalena honestly: she could go to market now and accept the discount, or she could spend three to four months refreshing the per-clinic CARF survey-readiness binders to a uniform Memorial Drive standard with the eight-person compliance and quality team driving the work, building a unified payor credentialing-and-renewal calendar across all major commercial, Medicaid, Tricare, and Medicare relationships, and formalizing a documented patient-cohort retention curve broken out by program, by payor type, and by clinic location. We said the second path would likely command a meaningfully better number from a wider range of buyers, especially a PE-backed addiction treatment consolidator with an underwriter that cared about CARF survey continuity, in-network credentialing transferability, and cohort retention defensibility. The realistic buyer pool for an $8.5 million revenue, $2.1 million EBITDA, four-clinic, 3,200-patient outpatient SUD platform with a 90 percent in-network payor base in Houston is concentrated but extremely well-capitalized, and each band of buyer prices the same platform differently. CGK is an active member of the International Business Brokers Association and the M&A Source, both of which give us deep visibility into the active addiction treatment buyer landscape, and we track the regulatory-and-policy environment through the National Association of Addiction Treatment Providers, the American Society of Addiction Medicine, and CARF International on accreditation standards. (For owners of ABA, autism, and IDD-focused practices outside the SUD category, see our behavioral health practices page when published.)
This is the part most brokers skip. Most brokers would have signed Kalena that day, taken her to market, and made the commission whether or not the deal was the best one for her. We told her to wait, even though it meant we did not get paid for four months and might never get paid at all if she changed her mind.
Kalena went home and waited. She spent the next four months working with her eight-person compliance and quality team to refresh the per-clinic CARF survey-readiness binders to a uniform Memorial Drive standard across Sugar Land, Pearland, and Cypress, building the unified payor credentialing-and-renewal calendar across each commercial carrier, each Texas Medicaid managed care organization, Tricare West, and Medicare Part B, formalizing the documented cohort retention curve broken out by program (MAT, IOP, PHP, telehealth MAT), by payor type, and by clinic location, tightening the Methasoft electronic medical record data hygiene across the trailing thirty-six months, and pulling together a hospital-ER referral attribution analysis that documented the per-hospital and per-ER discharge planner referral volume across Memorial Hermann, Houston Methodist, and HCA Houston Healthcare. She read background material on addiction treatment M&A through NAATP and on the regulatory-and-payor environment through ASAM. She called us back about four months later and said she was ready to sell an addiction treatment center that was finally in the shape it needed to be in.
What we did when Kalena came back.
What it takes to sell an addiction treatment center properly
When a physician is ready to sell an addiction treatment center with CGK, the speed of the on-ramp surprises them. We took Kalena’s platform to market in just over six weeks once she got us her updated financials, the refreshed per-clinic CARF survey-readiness binders, the unified payor credentialing-and-renewal calendar, the documented cohort retention curve broken out by program, by payor type, and by clinic location, the hospital-ER referral attribution analysis across Memorial Hermann, Houston Methodist, and HCA Houston Healthcare, the trailing thirty-six months of Methasoft electronic medical record data hygiene, the per-clinic patient census trends, the per-clinic average-length-of-stay analysis broken out by program, the DEA X-waiver compliance documentation across all four prescribing physicians, the controlled-substances reconciliation history, the criminal-justice-diversion referral attribution data from the Harris County and Fort Bend County diversion programs, the per-clinic lease terms on Memorial Drive, Sugar Land, Pearland, and Cypress, and the full P&L breakouts across all four sites and across the four program lines (MAT, IOP, PHP, telehealth MAT). The blind teaser went out to 31 buyers we had pre-qualified, a tighter funnel than other healthcare segments because the addiction treatment M&A buyer pool at this revenue band is structurally concentrated around a small group of well-capitalized PE-backed consolidators (fewer than fifteen active addiction treatment platforms operate at this acquisition band nationally).
Why the 90 percent in-network payor mix is the multiple anchor
This is the most important paragraph on the page, so we will say it directly. The 90 percent in-network mix Kalena built deliberately over eleven years is what made her practice command a premium multiple, and what made buyers willing to pay top-of-band price. PE-backed addiction treatment consolidators in 2026 structurally discount or refuse to acquire out-of-network outpatient SUD operators for three reasons. First, federal No Surprises Act enforcement and state insurance reform across most major states have crushed out-of-network billing margins on addiction treatment claims since 2022, with reimbursement rates trending toward in-network parity (and sometimes below) when payors invoke the qualifying-payment-amount methodology under the No Surprises Act independent dispute resolution process. Second, regulatory scrutiny on out-of-network addiction operators from the FTC, state attorneys general, and CMS has been brutal across 2023 to 2026, with multiple high-profile enforcement actions on patient-brokering, kickback, and balance-billing practices that historically subsidized the out-of-network model. Third, PE-backed consolidators will not roll up out-of-network operators because they cannot underwrite the regulatory risk against their own institutional limited-partner reporting requirements, and because their LP base demands clean, defensible, recurring-revenue cash flows from in-network commercial, Medicaid, Tricare, and Medicare reimbursement. The result is that an in-network addiction treatment platform at Kalena’s revenue and EBITDA band commands a meaningful premium over an out-of-network operator at the same trailing financials, often a one-to-two-turn EBITDA premium, because the buyer’s underwriter can stand behind the in-network reimbursement rates and the credentialing transferability through the integration window.
The buyer pool for a CARF-accredited, in-network outpatient SUD platform
Twenty-two of the thirty-one buyers signed NDAs and received the full Confidential Information Memorandum. Thirteen submitted Indications of Interest after data-room review. Seven advanced to Letters of Intent. We narrowed to five for management presentations. Three re-submitted refined LOIs after the management meetings. Two went into a final-final negotiation cycle. Buyers fell across four buckets we routinely use to think about how to sell an addiction treatment center: PE-backed addiction treatment consolidators (active across Nashville, Atlanta, Pittsburgh, and a handful of national platforms operating at the Acadia Healthcare, Discovery Behavioral Health, Pyramid Healthcare, Pinnacle Treatment Centers, BHG Holdings, and Recovery Centers of America tier, typically running multi-state roll-up theses with central regulatory, compliance, billing, and IT support, usually pricing on a 6.5x to 7.5x EBITDA band on diligence-clean in-network outpatient SUD platforms with documented CARF survey readiness, payor credentialing transferability, cohort retention defensibility, and DEA X-waiver compliance, and typically operating acquired clinics under their original brand names with central regulatory, compliance, billing, and IT support rather than absorbing them into a single national identity), regional Texas-based behavioral health operators (privately held, often physician-founded, expanding their Texas or Gulf Coast footprint through targeted acquisitions and typically operating acquired clinics under their original brand names with central administrative support, usually pricing on a 5.5x to 6.5x EBITDA band with stronger physician continuity expectations than PE buyers), hospital health systems running vertical-integration theses (the rarest buyer pool but the most strategically valuable when present, typically integrating acquired SUD outpatient platforms into their discharge-planning pipeline and behavioral health service lines, occasionally pricing at or above PE multiples when the strategic fit is right but slower to close because of board approval cycles), and individual physician-buyer or small-physician-group-buyer acquisitions (the rarest buyer pool at this band because the EBITDA size pushes the deal value above SBA capacity and physician-financing structures, typically focused on single-clinic acquisitions in the $200K to $500K EBITDA range). Each bucket prices the same platform differently.
Kalena decided between the top two LOIs. They were materially different. One was a slightly higher headline price from a regional Texas-based behavioral health operator with roughly $340 million in revenue across more than 25 acquired SUD outpatient and residential facilities, where the four Houston clinics would absorb into the operator’s central administrative playbook within sixty days, the four staff physicians would absorb under the operator’s standardized physician comp model (which sat below the comp model Kalena had built), the eighteen LCDC, LPC, and LMFT counselors and the twelve RN and LVN clinical staff would absorb under a different operations and scheduling rhythm, and Kalena would transition to a six-month medical-director-emeritus role with no continuing clinical-leadership presence. The other was a slightly lower headline price from a PE-backed addiction treatment consolidator with approximately $1.6 billion in revenue across more than 90 acquired SUD outpatient and residential facilities pre-acquisition, expanding its Texas and Gulf Coast footprint with Kalena’s four-clinic Houston platform as the southeast Texas anchor and the base for further Gulf Coast roll-up, with a long-hold thesis (10-plus years, positioning for a 2030+ second-bite or strategic exit). Under that LOI, the four clinics would continue to operate under their original brand name with central regulatory, compliance, billing, and IT support from the consolidator, the 64-person W-2 team would stay employed across the four sites, the four staff physicians would absorb at or above their existing comp under the consolidator’s clinical-leadership compensation framework with formal three-to-five-year stay arrangements tied to DEA X-waiver continuity, the eighteen LCDC, LPC, and LMFT counselors and the twelve RN and LVN clinical staff would retain their roles and pay structure, the eight case managers and fourteen administrative, billing, and intake personnel and the eight-person compliance and quality team would all retain their roles, the Methasoft electronic medical record and Welkin scheduling platform would be retained for the four Houston clinics through an 18-month integration window, the CARF accreditation would be preserved through a continuity-of-survey arrangement, and Kalena would step into a 18-month transition consulting role at one day per week and then move into a part-time medical-director-emeritus role flying in quarterly from Hawaii. We walked Kalena through what each LOI would actually deliver under realistic and pessimistic scenarios, including what the operational continuity would look like for her four staff physicians, her counseling team, her clinical staff, her case managers, her front-office team, and her eight-person compliance and quality team under each acquisition structure, and what the long-tenure MAT patient cohort would experience under each. The PE-backed consolidator deal was the better one for Kalena. The 18-month transition consulting role and the part-time medical-director-emeritus structure gave her the structural off-ramp she needed to spend the bulk of her time in Hawaii with her mother through the Parkinson’s progression. The team preservation kept her four staff physicians, her counseling team, her clinical staff, and her compliance and quality team in the roles they had earned. The Methasoft and Welkin platform preservation through the 18-month integration window kept the daily clinical rhythm intact through the post-close transition.
Through the whole process, the same CGK Managing Director who had taken Kalena’s first call four months earlier was the person walking her through every conversation.
The deal Kalena took to sell an addiction treatment center.
How the deal looks when you sell an addiction treatment center with CGK
This is the part of how to sell an addiction treatment center that gets the least attention in the trade press and the most attention from physicians who have actually closed a transaction: the structure of the consideration package matters more than the headline number, and the structure for an in-network, CARF-accredited, multi-clinic outpatient SUD platform with a deep MAT cohort and a hospital-ER referral pipeline is meaningfully different from the structure typical of every other healthcare segment CGK works in. Kalena’s deal closed roughly nine months after we restarted the engagement, a typical CGK addiction treatment window because addiction treatment M&A involves CMS and Texas Medicaid change-of-ownership review on each clinic, payor credentialing transfer review across each commercial carrier and each Texas Medicaid managed care organization plus Tricare West and Medicare Part B, transfer of the DEA X-waiver compliance documentation across all four prescribing physicians, transfer of the CARF accreditation through a continuity-of-survey arrangement, transfer of the Methasoft electronic medical record and the Welkin scheduling platform licenses, transfer of approximately 3,200 active patient charts under HIPAA-compliant chart-transfer protocols, change-of-control consents on hospital-ER referral relationships with Memorial Hermann, Houston Methodist, and HCA Houston Healthcare, change-of-control consents on the criminal-justice-diversion referral relationships with Harris County and Fort Bend County, and a more involved pre-close due diligence cycle on the per-clinic CARF survey-readiness binders and the cohort retention curve than typical large-band healthcare M&A. The buyer was the PE-backed addiction treatment consolidator with approximately $1.6 billion in revenue across more than 90 acquired SUD outpatient and residential facilities pre-acquisition, expanding its Texas and Gulf Coast footprint with Kalena’s four-clinic Houston platform as the southeast Texas anchor and the base for further Gulf Coast roll-up, operating on a 10-plus year long-hold thesis with a 2030+ second-bite or strategic exit horizon. The acquisition structure was an asset purchase rather than a stock purchase, with the four clinics folding into the consolidator at close, the 64-person W-2 team staying employed across the four locations, the four staff physicians absorbing at or above their existing comp with three-to-five-year stay arrangements tied to DEA X-waiver continuity, the counseling team and clinical staff retaining their roles and pay structure, the case managers and the front-office team and the eight-person compliance and quality team retaining their roles, the Methasoft and Welkin platforms retained through an 18-month integration window, the CARF accreditation preserved through a continuity-of-survey arrangement, the original clinic brand name retained with central consolidator support layered behind it, and Kalena transitioning to an 18-month transition consulting role at one day per week followed by a part-time medical-director-emeritus role flying in quarterly from Hawaii.
The total deal economic value was approximately $15.3 million, roughly 7.3 times trailing EBITDA, a premium addiction treatment multiple driven by the 90 percent in-network payor mix, the CARF accreditation, the 78 percent twelve-month MAT retention rate against an industry average closer to 50 to 60 percent, the four-clinic geographic moat across the high-density Houston metro substance use disorder population, the hospital-ER referral pipeline through Memorial Hermann, Houston Methodist, and HCA Houston Healthcare, the criminal-justice-diversion referral flow through Harris County and Fort Bend County, the DEA X-waiver compliance documented across all four prescribing physicians, the bilingual English-Spanish counseling capacity, the Methasoft and Welkin technology standardization across the four clinics, the eleven-year operating history under a single physician founder, and the documented cohort retention curve and unified payor credentialing-and-renewal calendar Kalena had built during the four-month wait period. About 72 percent of it came as cash at closing, in line with what a sophisticated PE-backed addiction treatment consolidator typically structures on a multi-clinic in-network outpatient SUD platform. About 8 percent was held back in escrow for 18 months, an extended escrow window because the addiction treatment CMS and Texas Medicaid change-of-ownership audit cycle and the payor credentialing transfer cycle both extend past the typical twelve-month healthcare escrow window. The remaining 20 percent was a rollover-as-equity stake into the consolidator’s holding company, with Kalena’s existing equity converting into the consolidator’s holding-company partnership interests on a vesting schedule tied to her continued 18-month transition consulting role and her part-time medical-director-emeritus presence (addiction treatment rollover percentages run 15 to 25 percent because the consolidators specifically tie part of the sale value to the medical director’s continued clinical-leadership presence for DEA X-waiver continuity and CARF survey continuity). The numbers add up to one hundred. Wire hit on a Friday morning at 10:47 a.m. while Kalena was at the Memorial Drive main clinic preparing for a scheduled clinical update with the family of a 26-year-old patient who had just completed his 18-month MAT milestone.
Kalena stayed on as a transition consultant for the consolidator’s southeast Texas region for 18 months after closing, one day per week, so she could personally introduce each of the four staff physicians to the consolidator’s central regulatory and clinical-leadership team, walk her director of nursing through the consolidator’s central compliance, billing, and IT playbook for outpatient SUD treatment, oversee the integration of the Methasoft electronic medical record and Welkin scheduling platform onto the consolidator’s national clinical-data infrastructure on a managed timeline, oversee the CARF survey continuity arrangement through the next survey cycle, and shape the consolidator’s southeast Texas Gulf Coast expansion strategy across two adjacent metro markets the consolidator was actively in conversation with in Beaumont-Port Arthur and the Lake Charles, Louisiana corridor. After 18 months, Kalena stepped into a part-time medical-director-emeritus role flying in quarterly from Honolulu, with the rollover-as-equity stake in the consolidator’s holding company continuing to vest on a multi-year schedule tied to the platform’s overall performance and her continued quarterly clinical-leadership presence.
What happened to Kalena’s people and her patients.
The people-side of how to sell an addiction treatment center usually weighs heavier on the founding physician than the financial-side, even when the financial-side is what triggers the call to a broker in the first place. Kalena cared most about her four staff physicians (the three MDs board-certified in addiction medicine and the psychiatrist who anchored the dual-diagnosis caseload), her eighteen LCDC, LPC, and LMFT counselors who had built the IOP and PHP groups, her twelve RN and LVN clinical staff who handled medication administration and triage, her eight case managers who coordinated the parole-and-probation, hospital-discharge, and community-resource workflows, her fourteen front-office administrative, billing, and intake personnel, and her eight-person compliance and quality team that owned the CARF survey, the DEA X-waiver documentation, the state SUD licensing, and the payor credentialing rhythm. She also cared about the patient base: roughly 3,200 active patients across the four clinics, the 14-month average length of stay in the MAT program, the 78 percent twelve-month MAT retention rate, the long-tenure cohort that had been with the practice for two-to-five years, and the family members and parole officers and ER discharge planners who were part of the extended care network. The PE-backed consolidator buyer was a long-hold operator that intended to actually preserve the operational rhythm of the four Houston clinics through the integration window, operating each clinic under its original brand name with central regulatory, compliance, billing, and IT support layered behind it rather than absorbing them into a single national identity. That made the people part substantially cleaner than it would have been under the higher-headline-price regional Texas behavioral health operator deal that wanted to absorb the platform into a single central administrative playbook within sixty days.
The buyer kept all 64 W-2 employees, honored the existing pay structure across staff physicians, counselors, clinical staff, case managers, front-office, and compliance and quality team, and committed to retaining the four staff physicians under three-to-five-year stay arrangements tied to DEA X-waiver continuity, the eighteen LCDC, LPC, and LMFT counselors continuing in their IOP and PHP roles, the twelve RN and LVN clinical staff continuing on medication administration and triage, the eight case managers continuing on the parole-and-probation, hospital-discharge, and community-resource workflows, the fourteen front-office administrative, billing, and intake personnel continuing in their roles, and the eight-person compliance and quality team continuing on the CARF survey, the DEA X-waiver documentation, the state SUD licensing, and the payor credentialing rhythm. The 3,200 active patient cohort transferred under HIPAA-compliant chart-transfer protocols on a managed timeline, with continuity of care language preserved across the consolidator’s central clinical platform. The Methasoft electronic medical record and Welkin scheduling platform were retained for the four Houston clinics through an 18-month integration window before any consolidation onto the consolidator’s national clinical-data infrastructure. The CARF accreditation transferred under a continuity-of-survey arrangement that preserved the practice’s top-22-percent regulatory standing through the next survey cycle. The DEA X-waiver compliance documentation transferred under formal regulatory-transfer language inside the asset purchase, with the four prescribing physicians’ compliance status preserved through the transition. The hospital-ER referral relationships with Memorial Hermann, Houston Methodist, and HCA Houston Healthcare transferred under change-of-control consents that preserved the discharge-planning workflow through the rebrand-free integration window. The criminal-justice-diversion referral relationships with Harris County and Fort Bend County diversion programs transferred under change-of-control consents. The per-clinic real-property leases on Memorial Drive, Sugar Land, Pearland, and Cypress transferred cleanly under the consolidator’s real-estate group. The bilingual English-Spanish counseling capacity stayed intact because the team and the technology and the brand and the operational rhythm stayed in place.
Kalena was at the Memorial Drive main clinic on a Friday morning when the wire confirmation came through. Addiction treatment closings often happen at the end of the week to coincide with month-end clinical reporting cycles. She walked out to the patient family-waiting area where she had a scheduled clinical update with the family of a 26-year-old patient who had just completed his 18-month MAT milestone. She did not interrupt the family meeting. She finished it. Then she drove home to her house in Memorial Park, sat on the back deck overlooking the bayou, and called her mother in Honolulu. She said in Hawaiian: “Pau, makuahine.” It is done, mother. Her mother answered, slowly because of the Parkinson’s, but clearly: “Mahalo, kauʻiokalani.” Thank you, my heavenly beloved one. Daniel came home from Texas Children’s Hospital around 6 p.m., and the two of them sat on the deck and drank black coffee and started actually planning the Hawaii cadence week by week for the first time. David came home from school at one point and waved at them through the kitchen window. Kalena waved back, and Daniel nodded, and that was the evening.
What Kalena told us afterward.
Why physicians who sell an addiction treatment center with CGK keep coming back
Most physicians who sell an addiction treatment center do not call the broker again in the first year. The ones who do call usually want to talk about the parts of the engagement that, in retrospect, mattered more than they realized at the time. About six months after closing, while she was back in Houston for her quarterly medical-director-emeritus visit, Kalena called the Managing Director who had run her engagement. She said two things that the Managing Director still tells new sellers about.
The first was about the four-month wait. She said: “Three of the buyers who had been calling me were ready to sign LOIs in forty-five days, and two different healthcare M&A consultants I had talked to before you told me they could take me to market right then with the per-clinic CARF survey-readiness binders still uneven across Sugar Land, Pearland, and Cypress, with the payor credentialing-and-renewal calendar still scattered across each major commercial carrier and each Texas Medicaid managed care organization, and with the cohort retention curve still undocumented. The reason I sold with you is that you told me the truth about how my 90 percent in-network payor base, my CARF accreditation, my 78 percent MAT retention rate, my hospital-ER referral pipeline, and my four-clinic geographic moat were actually being valued by a sophisticated PE-backed addiction treatment consolidator underwriter, the truth about what the per-clinic CARF survey-readiness refresh would buy me in LOI conversations four months later, the truth about what the unified payor credentialing-and-renewal calendar would buy me in management-presentation conversations, and the truth about what the documented cohort retention curve would buy me in investment-committee approval. You told me what would happen to the price if I went out without fixing those things. I would have left two-and-a-half million dollars on the table, my four staff physicians would have folded into a worse comp tier under a different operator, and my counseling team and my eight-person compliance and quality team would have absorbed under a buyer with a tighter integration timeline.”
The second was about who she sold to. She said: “I almost signed with the higher-headline-price regional Texas behavioral health operator because the number on the top line was bigger and they told me they could close in ninety days. The fact that you walked me through what each buyer would actually do with my four staff physicians, my counseling team, my clinical staff, my case managers, my front-office team, my eight-person compliance and quality team, the four clinics I had built across eleven years, the CARF accreditation I had spent three years earning, and the 90 percent in-network payor mix I had spent eleven years building one contract at a time, what each buyer’s regulatory-and-clinical integration thesis would mean for the long-tenure MAT cohort three and five years out, and how a PE-backed consolidator with a brand-preservation thesis was structurally different from a regional operator with a sixty-day full-absorption thesis, is a conversation I never even thought to have until you raised it. I sold to a buyer who is actually going to keep the operational rhythm and the brand and the team and the clinical leadership intact through the long-hold window, and the 18-month transition consulting role and the part-time medical-director-emeritus structure you negotiated is what is letting me spend the bulk of my time in Hawaii with my mother on my own timeline. That was not on the original LOI. You pushed for it.”
This is what we mean when we say we sit with you in the decision, not just the transaction. Kalena is one composite story, but the pattern is real. The physicians we work with who decide to sell an addiction treatment center usually find their way to us through versions of Kalena’s situation, and the relationships start with a long listening session and a free walkthrough, not a pitch.
Ready to sell an addiction treatment center? Where are you in Kalena’s story?
If you are starting to think about how to sell an addiction treatment center, we should talk. There is no commitment and no pressure. The first conversation is free. The valuation walkthrough that follows is free when you are seriously thinking about selling, whether that is in a year, five years, or longer. We only charge for formal written valuations, and only when you actually need one for a partnership buyout, estate planning, or another documentary purpose. Submit the form and a senior CGK Managing Director will reach out within one business day.
If you are Kalena at month 1: just exploring
You are not sure if you want to sell yet. The addiction treatment M&A landscape keeps shifting under federal No Surprises Act enforcement and state insurance reform, your in-network payor mix is meaningful but the unified credentialing-and-renewal calendar is scattered, your CARF accreditation is real but the per-clinic survey-readiness binders are uneven across satellite sites, your MAT retention rate is meaningful but the cohort curve is undocumented, your DEA X-waiver compliance is documented but not consolidated for buyer review, your Methasoft and Welkin data hygiene is uneven across the trailing thirty-six months, eleven years of running the platform is starting to tell you something, your family circumstances are pulling you toward a different geography, you are curious about how a buyer would value your MAT versus IOP versus PHP mix, or maybe a PE-backed addiction treatment consolidator or a regional behavioral health operator has been calling you. Most of our best engagements start here. Submit the form and we will schedule a working session. You walk away with a real number and a clear sense of what to do next, with no obligation to do anything.
If you are Kalena at month 4: ready to go
You have done the work to clean up the platform. The financials are tight. Your per-clinic CARF survey-readiness binders are refreshed to a uniform standard across the main clinic and each satellite. Your unified payor credentialing-and-renewal calendar is documented across each commercial carrier, each state Medicaid managed care organization, Tricare, and Medicare. Your patient-cohort retention curve is broken out by program, by payor type, and by clinic location. Your hospital-ER referral attribution analysis is documented across each referring hospital and ER discharge planner. Your DEA X-waiver compliance documentation is consolidated across all prescribing physicians. Your Methasoft electronic medical record data is pulled into a buyer-grade report for the trailing thirty-six months. Your physician and clinical-leadership succession plan is named and pre-negotiated. Maybe a buyer is already in the conversation. You want to run a real process. Submit the form and we will be in touch within a business day to talk about timing, scope, and what your first 30 days as a CGK seller would look like.
If you are not sure where you are
Most physicians are not sure. Submit the form and start with the conversation. We will figure out together where you are. We are equally happy to tell you to wait twelve months as we are to take you to market in six weeks.
Or call us directly at (888) 858-7191.
Start your own story
A senior CGK Managing Director will respond within one business day. Strictly confidential. For physician-owners of addiction treatment centers and outpatient substance use disorder platforms doing $1.5M+ in annual revenue, including medication-assisted treatment programs, intensive outpatient programs, partial hospitalization programs, and telehealth-delivered MAT operators. The first conversation and the valuation walkthrough that follows are free for any seller seriously thinking about selling, on any horizon.
Confidential. No obligation. Direct routing to a named CGK business broker, not a junior screener.
One of these eight people would lead your engagement.
When you decide to sell an addiction treatment center with CGK, one named senior Managing Director stays with you from the first call through the wire transfer, just like Kalena’s Managing Director stayed with her for four months and then for the engagement that followed. Our Managing Directors come from Wall Street investment banks, hedge funds, Fortune 500 corporate finance, and operating-business leadership. Cornell MBA. U Chicago Booth MBA. CFA. CMT. Naval Academy. Goldman Sachs. Merrill Lynch. Deutsche Bank. AIG. T. Rowe Price.
What sellers say after they sell an addiction treatment center (and other businesses) with CGK
I could not be happier with the experience I had selling my business with CGK. Greg did a detailed analysis of my business and helped me price and position it right for the market. After receiving multiple offers at full asking price, the rest of the process went very smoothly, and we closed in less than two months.
Hanna M.Selling my business was a once-in-a-lifetime experience, and I’m incredibly grateful to have had Wes by my side throughout the process. He brought perspective, pushed when necessary, and always had my best interests in mind. His experience and strategic approach allowed me to maximize the sale price while minimizing long-term risk and obligations. If I had to do it all over again, I wouldn’t hesitate to choose him as my broker.
Adam NevilleDerik located multiple interested strategic buyers that produced more than one serious offer. The negotiations were tough but Greg and Derik’s experience helped us overcome. We got a great result for our employees and for the owners. We would recommend them without reservation.
Bob TaylorWe sold a business that was 47 years old and being run by second generation within a year of working with Wes. CGK has a system that attracts serious prospects to review opportunities. Wes was able to make the overwhelming feeling of selling easy and to a certain extent enjoyable. I never felt alone or in the dark throughout the entire process.
Jennifer WilliamsWe decided to sell our company in 2025. Talked to another M&A company in the Houston area. We felt very comfortable with Greg and Matthew at CGK. Could not have made a better choice. From day 1 till final closing and even after 30+ days, they have been here helping us with documents and support during the transition. Thanks can not be said enough.
Rickey ThomasInside the Blueprint, on Bloomberg TV and Fox Business News.
Kalena’s husband Daniel, the pediatric oncologist at Texas Children’s Hospital, was the one who first sent her a clip of CGK on Bloomberg. He had been watching the segment in the kitchen on a Saturday morning while David was studying for a calculus test, and he recognized the firm name from a healthcare M&A trade article about how to sell an addiction treatment center that Kalena had read a few months earlier. He texted her the link with a note that read “Look at this. This is the firm. Same one from your trade article.” CGK Business Sales is featured on Inside the Blueprint, the syndicated business television series. Our episode aired on Bloomberg TV and Fox Business News. Watch the segment, then start a confidential conversation.
The CGK office Kalena called was the CGK Houston office. Yours might be one of these.
When you sell an addiction treatment center with CGK, whichever office you reach, you get the entire firm. Kalena worked with a CGK Managing Director based out of the firm’s Houston office covering the broader Gulf Coast metro, but her deal benefited from a buyer pool we sourced firm-wide, including the PE-backed addiction treatment consolidator that ultimately won the engagement and is now using the four Houston clinics as its southeast Texas anchor and the base for further Gulf Coast roll-up. Click any city to learn about our local presence and the named Managing Director leading that market.
Other Questions Kalena and Other Addiction Treatment Sellers Ask Us
Practical answers to what comes up before, during, and after the kind of engagement Kalena went through, when you sell an addiction treatment center with CGK.